search
Back to results

BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations?

Primary Purpose

Hypertension, Dementia

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Bedtime administration of the participant's pre-existing antihypertensive medications
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hypertension focused on measuring Pragmatic, Primary Care, Chronotherapy, Administrative Data, Behaviourism, Sundowning, Stroke, Myocardial Infarction, Heart Failure, Hip Fracture, Nursing Home, Long Term Care

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Hypertension diagnosis as indicated by ≥ 2 such billing diagnoses at any time in the administrative claims data by any provider
  2. ≥ 1 once daily BP lowering medication
  3. Resident in a participating long term care facility.

Exclusion Criteria:

  1. Personal history of glaucoma or use of glaucoma medications. Glaucoma is an exclusion because nocturnal hypotension (i.e. excessively low blood pressure while sleeping) has been associated with ischemic optic neuropathy in such patients.
  2. Any patient / family member or treating physician (all of whom will be notified of the LTC facilities participation in this initiative) requesting the patient not participate.

Sites / Locations

  • Multiple Alberta Long Term Care Facilities

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Bedtime Antihypertensive Medications

Morning Antihypertensive Medications

Arm Description

The LTC facility's pharmacist will switch all once daily antihypertensive medications, one at a time as tolerated, to bedtime. Blood pressure lowering medications taken more than once per day are left alone.

No change to blood pressure medication timing is made. By default, most patients are using once daily antihypertensive medications in the morning at baseline.

Outcomes

Primary Outcome Measures

Composite of Major Adverse Cardiovascular Events
Composite of all-cause death and hospital admission or emergency room visit for acute coronary syndrome / myocardial infarction, heart failure, or stroke - as recorded in governmental health claims databases

Secondary Outcome Measures

All Cause Mortality
All cause death - as recorded in governmental health claims databases
Hospitalization for Acute Coronary Syndrome / Myocardial Infarction
Hospitalization or emergency room visit for acute coronary syndrome / myocardial infarction - as recorded in governmental health claims databases
Hospitalization for Stroke
Hospitalization or emergency room visit for stroke - as recorded in governmental health claims databases
Hospitalization for Congestive Heart Failure
Hospitalization or emergency room visit for congestive heart failure - as recorded in governmental health claims databases
All Cause Unplanned Hospitalization
All cause hospitalization or emergency room visit excluding elective surgeries or booked procedures / planned follow-up care - as recorded in governmental health claims databases
Non-vertebral Fracture
Any physician billing (hospital or community) for a fracture other than a vertebral fracture (which might indicate a vertebral compression fracture secondary to osteoporosis, and not trauma)
Number of Patients with a Fall in the Last 30 days
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization
Number of Patients with "Deteriorated Cognition Relative to Status 90 Days Prior"
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization
Number of Patients with Urinary Incontinence
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Includes "occasionally incontinent" or more frequent, which equates to 2 or more episodes per week.
Number of Patients with Partial or Full Thickness Decubitus Skin Ulceration ("Bed Sores")
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Requires some degree of skin breakdown and not just erythema (i.e. stages 2 to 4).
Acute Care Costs
Calculated from all hospitalizations using the resource intensity weight (RIW) and length of stay (LOS) as recorded in governmental health claims data
Total Cost of Care
Acute care costs + medication costs + physician billings + nursing / facility costs as recorded in governmental health claims data. Nursing / facility costs will be estimated from level of care and duration of stay

Full Information

First Posted
July 29, 2019
Last Updated
June 6, 2023
Sponsor
University of Alberta
Collaborators
Alberta Innovates Health Solutions, Canadian Institutes of Health Research (CIHR), EnACt, Alberta Health services
search

1. Study Identification

Unique Protocol Identification Number
NCT04054648
Brief Title
BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations?
Official Title
Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations? The "BedMed-Frail" Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
May 14, 2020 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Alberta
Collaborators
Alberta Innovates Health Solutions, Canadian Institutes of Health Research (CIHR), EnACt, Alberta Health services

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
High blood pressure (present in 1 of 5 Canadian adults) increases the risk of heart attack and stroke. Blood pressure lowering pills reduce this risk - but perhaps not optimally. A Spanish study suggests that using blood pressure pills at bedtime, instead of in the morning (when they are most commonly used), reduces death, heart attack, and stroke by more than 50%. If true, a switch to bedtime prescribing would have more impact on the health of those with high blood pressure than whether high blood pressure is treated at all. BedMed, a community-based Canadian primary care trial, is already running and looking both to validate the findings of this Spanish study and to determine whether there might be unrecognized harms of bedtime use (such as more falls and fractures as a result of lower overnight blood pressure). One very important population that is likely to be more sensitive to the effects of medications, and almost always excluded from randomized trials, are the frail elderly (such as those who are resident in nursing homes). In order to have the greatest information about the safety and effectiveness of bedtime blood pressure medications, the BedMed team is additionally conducting a similar trial to BedMed in nursing homes ("BedMed-Frail" - the subject of this trial registration) to determine whether the risks and benefits of bedtime prescribing differ in this highly understudied population. Basics of the trial: When patients are admitted to nursing homes, neither they nor their physicians are consulted about the timing of blood pressure medication. Unless explicitly stated to be otherwise, blood pressure pills are instead largely arbitrarily assigned for morning use by default. Given there is evidence that bedtime administration may be safer, the nursing homes participating in BedMed-Frail will have each hypertensive resident randomized to either continue with morning blood pressure medication use, as is their norm, or to have their facility's pharmacist gradually switch each residents blood pressure pills to bedtime. Over a period of roughly 3 years, health outcomes in these facilities will be tracked using routinely collected electronic health data to determine differences in things like hospitalization, death, or hip fractures - and at the end of the study the investigators hope to determine whether or not the recommendations for blood pressure medication timing in frail older adults should differ from those for the general population.
Detailed Description
The BedMed trial (led out of the University of Alberta and funded by both Alberta Innovates Health Solutions, and the Canadian Institutes for Health Research) is a pragmatic multi-provincial trial intended to determine whether bedtime antihypertensive use, as compared to conventional morning use, reduces major adverse cardiovascular events in community dwelling primary care patients. BedMed-Frail, led by the same group of investigators, is a complementary but separate randomized trial evaluating whether the risks and benefits of bedtime antihypertensive use differ in a long-term care (LTC) population. To accomplish this, within participating Alberta LTC and supportive living facilities, eligible residents with hypertension will be randomized at the patient level to the antihypertensive medication timing intervention (i.e. bedtime versus continued morning use). Trial outcomes and baseline characteristics are drawn from routinely collected electronic health data - using both provincial administrative health claims data and the Resident Assessment Instrument Minimum Data Set (RAI-MDS), which is a standard instrument for collecting clinical information in Canadian LTC facilities. BedMed-Frail is event driven, receiving quarterly reporting of total events from the Alberta Support for Patient Oriented Research (SPOR) Unit's Data Platform. The trial will end upon observation of 368 primary outcome events. Upon observation of half that number, an independent data safety monitoring board (IDSMB) chaired by Dr. James Wright (Cochrane Hypertension Review Group Co-ordinating Editor) will examine all available outcomes. If p is ≤ 0.001 for benefit (the Haybittle-Peto boundary - recommended to reduce the chance of stopping too early and magnifying benefit), or if p is ≤ 0.05 for harm, the IDSMB will apply clinical judgement and make recommendations to the steering committee on whether the trial should break early. The outcomes of BedMed-Frail are primarily designed to be analogous to the cardiovascular and safety outcomes monitored for in the community BedMed study. However BedMed-Frail is also examining for differences in behaviour issues between groups. Both behavioural problems, and blood pressure, have circadian rhythms. Blood pressure is normally lower overnight and behavioural problems in long term care residents typically worsen during the same period - a phenomenon known as "sundowning". Conceivably, there could be a relationship between the two such that behaviour problems might improve, or worsen, with bedtime antihypertensive use.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Dementia
Keywords
Pragmatic, Primary Care, Chronotherapy, Administrative Data, Behaviourism, Sundowning, Stroke, Myocardial Infarction, Heart Failure, Hip Fracture, Nursing Home, Long Term Care

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Event-driven Prospective Randomized Open Blinded End-Point (PROBE) Randomized Trial.
Masking
Outcomes Assessor
Masking Description
Outcomes are drawn from administrative claims data which derive from hospital separations (diagnoses and procedures) and physician billings. The acute care providers submitting the billings which define our outcomes will typically be meeting the patient for the first time, unaware of the patient's participation in BedMed-Frail, and unaware of the facility's administration time for once daily antihypertensives.
Allocation
Randomized
Enrollment
875 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bedtime Antihypertensive Medications
Arm Type
Active Comparator
Arm Description
The LTC facility's pharmacist will switch all once daily antihypertensive medications, one at a time as tolerated, to bedtime. Blood pressure lowering medications taken more than once per day are left alone.
Arm Title
Morning Antihypertensive Medications
Arm Type
No Intervention
Arm Description
No change to blood pressure medication timing is made. By default, most patients are using once daily antihypertensive medications in the morning at baseline.
Intervention Type
Other
Intervention Name(s)
Bedtime administration of the participant's pre-existing antihypertensive medications
Intervention Description
Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
Primary Outcome Measure Information:
Title
Composite of Major Adverse Cardiovascular Events
Description
Composite of all-cause death and hospital admission or emergency room visit for acute coronary syndrome / myocardial infarction, heart failure, or stroke - as recorded in governmental health claims databases
Time Frame
3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)
Secondary Outcome Measure Information:
Title
All Cause Mortality
Description
All cause death - as recorded in governmental health claims databases
Time Frame
3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)
Title
Hospitalization for Acute Coronary Syndrome / Myocardial Infarction
Description
Hospitalization or emergency room visit for acute coronary syndrome / myocardial infarction - as recorded in governmental health claims databases
Time Frame
3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)
Title
Hospitalization for Stroke
Description
Hospitalization or emergency room visit for stroke - as recorded in governmental health claims databases
Time Frame
3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)
Title
Hospitalization for Congestive Heart Failure
Description
Hospitalization or emergency room visit for congestive heart failure - as recorded in governmental health claims databases
Time Frame
3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)
Title
All Cause Unplanned Hospitalization
Description
All cause hospitalization or emergency room visit excluding elective surgeries or booked procedures / planned follow-up care - as recorded in governmental health claims databases
Time Frame
3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)
Title
Non-vertebral Fracture
Description
Any physician billing (hospital or community) for a fracture other than a vertebral fracture (which might indicate a vertebral compression fracture secondary to osteoporosis, and not trauma)
Time Frame
3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)
Title
Number of Patients with a Fall in the Last 30 days
Description
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization
Time Frame
4.5 Months (Average - will occur within a 3 to 6 month post randomization window)
Title
Number of Patients with "Deteriorated Cognition Relative to Status 90 Days Prior"
Description
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization
Time Frame
4.5 Months (Average - will occur within a 3 to 6 month post randomization window)
Title
Number of Patients with Urinary Incontinence
Description
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Includes "occasionally incontinent" or more frequent, which equates to 2 or more episodes per week.
Time Frame
4.5 Months (Average - will occur within a 3 to 6 month post randomization window)
Title
Number of Patients with Partial or Full Thickness Decubitus Skin Ulceration ("Bed Sores")
Description
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Requires some degree of skin breakdown and not just erythema (i.e. stages 2 to 4).
Time Frame
4.5 Months (Average - will occur within a 3 to 6 month post randomization window)
Title
Acute Care Costs
Description
Calculated from all hospitalizations using the resource intensity weight (RIW) and length of stay (LOS) as recorded in governmental health claims data
Time Frame
3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)
Title
Total Cost of Care
Description
Acute care costs + medication costs + physician billings + nursing / facility costs as recorded in governmental health claims data. Nursing / facility costs will be estimated from level of care and duration of stay
Time Frame
3 years (Estimate Only - study continues until 368 participants have experienced primary outcome events)
Other Pre-specified Outcome Measures:
Title
Number of Participants with "Behavioural Symptoms that are Present a Minimum of 4 Days per Week and Not Easily Altered" Including a) Wandering, b) Verbal Abuse, c) Physical Abuse, d) Socially Inappropriate or Disruptive Behaviour, or e) Resisting Care
Description
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization
Time Frame
4.5 Months (Average - will occur within a 3 to 6 month post randomization window)
Title
Number of Participants with Receipt (last 7 days) of Antipsychotic Medication or Physical Restraints
Description
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Physical restraints include trunk restraints, limb restraints, or a chair that prevents rising, but does not include bedrails.
Time Frame
4.5 Months (Average - will occur within a 3 to 6 month post randomization window)
Title
Receipt of Anti-Anxiety Medication on 3 or more of the Last 7 Days
Description
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization
Time Frame
4.5 Months (Average - will occur within a 3 to 6 month post randomization window)
Title
Receipt of a Bedtime Sleeping Pill on 3 or More of the Last 7 Days
Description
As recorded in the first quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization
Time Frame
4.5 Months (Average - will occur within a 3 to 6 month post randomization window)
Title
Number of Participants Indicated by Nursing to Have at Least One "Indicator of Depression or Anxiety" Almost Daily in the Last 30 Days
Description
As recorded by a nurse in the First Quarterly Minimum Data Set (MDS) report recorded at the care facility in the 3 to 6 month window following randomization. Applies to 16 discrete mood and anxiety related observations of the resident, any one of which being listed as present 6 or more days per week would qualify
Time Frame
4.5 Months (Average - will occur within a 3 to 6 month post randomization window)
Title
Proportion of BP Medication Doses Taken at Bedtime (Process Outcome)
Description
Obtained from the "directions for use" field in Pharmaceutical Information Network (PIN) data. For this calculation, medications dosed more than once a day are considered as 1/2 dose in the AM and 1/2 dose in the PM
Time Frame
Through study duration, up to 3 years, broken down monthly
Title
Use of at Least One Once Daily BP Medication at Bedtime (Process Outcome)
Description
Obtained from the "directions for use" field in Pharmaceutical Information Network (PIN) data.
Time Frame
Through study duration, up to 3 years, broken down monthly

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Hypertension diagnosis as indicated by ≥ 2 such billing diagnoses at any time in the administrative claims data by any provider ≥ 1 once daily BP lowering medication Resident in a participating long term care facility. Exclusion Criteria: Personal history of glaucoma or use of glaucoma medications. Glaucoma is an exclusion because nocturnal hypotension (i.e. excessively low blood pressure while sleeping) has been associated with ischemic optic neuropathy in such patients. Any patient / family member or treating physician (all of whom will be notified in advance of the LTC facilities participation in this initiative) requesting the patient not participate.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott R Garrison, MD, PhD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
Facility Information:
Facility Name
Multiple Alberta Long Term Care Facilities
City
Edmonton
State/Province
Alberta
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Although we hope to make a de-identified participant-level version of our final analytic dataset publicly available on our website (www.PragmaticTrials.ca), and will request to do so, this requires the permission of Alberta Health Services, who must weigh the privacy concerns.
IPD Sharing Time Frame
If approval from Alberta Health Services is obtained, data will be posted co-incident with the main results publication and intended for long-term availability.
IPD Sharing Access Criteria
The data will be downloadable in the form of an Excel spreadsheet for anyone who wishes to access it. No application process will be necessary.
IPD Sharing URL
http://PragmaticTrials.ca

Learn more about this trial

BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations?

We'll reach out to this number within 24 hrs